Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Prospective Randomized Phase III Trial to Determine the Benefit of Adjuvant Chemotherapy Using Gemcitabine and Cisplatin in Nasopharyngeal Carcinoma Patients With Residual EBV DNA Following Primary Radiotherapy With or Without Concurrent Cisplatin

NCT00370890 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT00370890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00370890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Prospective Randomized Phase III Trial to Determine the Benefit of Adjuvant Chemotherapy Using Gemcitabine and Cisplatin in Nasopharyngeal Carcinoma Patients With Residual EBV DNA Following Primary Radiotherapy With or Without Concurrent Cisplatin
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 3
Overall status
Completed
Start date
September 4, 2006
Completion date
October 26, 2021
Enrollment
104 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal cancer